DoW Alzheimerâs Transforming Research Award
Dept. of the Army -- USAMRAA
Funding Amount
$4,000,000 total
Deadline
September 24, 2026
112 days left
Grant Type
federal
Overview
DoW Alzheimerâs Transforming Research Award
Summary: The fiscal year 2026 (FY26) Alzheimerâs Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimerâs disease and/or Alzheimer's disease related dementias (AD/ADRD). Distinctive Features: ⢠Applications must address at least one of the following focus areas: â Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. â Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD. ⢠Clinical research is allowed, however clinical trials and animal research are prohibited. ⢠Preliminary data are required. ⢠Community collaboration is required for research prospectively enrolling human subjects. ⢠Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet
Details
- Agency: Dept. of the Army -- USAMRAA
- Department: Department of Defense
- Opportunity #: HT942526AZRPTRRA
- Total Funding: $4,000,000
- Expected Awards: 4
- Instrument: grant
Eligibility
Eligible Applicant Types
Focus Areas & Funding Uses
Fields of Work
Categories
Browse similar grants by category
Related Grants
Similar grants from this funder and related organizations
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
September 7, 2026
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
September 7, 2026
Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
September 25, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $400,000
Deadline
May 26, 2027
NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $200,000
Deadline
May 26, 2027
Ready to apply for DoW Alzheimerâs Transforming Research Award?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found DoW Alzheimerâs Transforming Research Award. Now let's win it.